9/19/2025

Morphine Sulfate Extended-Release Tablets

Products Affected - Description

- MS Contin oral extended release tablet, Rhodes, 100 mg, bottle, 100 count, NDC 42858-0799-01 - discontinued
- MS Contin oral extended release tablet, Rhodes, 200 mg, bottle, 100 count, NDC 42858-0900-01 - discontinued
- Morphine sulfate oral extended release tablet, Major, 100 mg, unit-dose blister pack, 100 count, NDC 00904-6560-61 - discontinued
- Morphine sulfate oral extended release tablet, Major, 15 mg, unit-dose blister pack, 100 count, NDC 00904-6557-61 - discontinued
- Morphine sulfate oral extended release tablet, Major, 30 mg, unit-dose blister pack, 100 count, NDC 00904-6558-61 - discontinued
- Morphine sulfate oral extended release tablet, Major, 60 mg, unit-dose blister pack, 100 count, NDC 00904-6559-61 - discontinued
- Morphine sulfate oral extended release tablet, Sun Pharma, 100 mg, bottle, 100 count, NDC 63304-0452-01
- Morphine sulfate oral extended release tablet, Teva, 100 mg, bottle, 100 count, NDC 00228-4323-11 - discontinued
- Morphine sulfate oral extended release tablet, Teva, 15 mg, bottle, 100 count, NDC 00228-4270-11 - discontinued
- Morphine sulfate oral extended release tablet, Teva, 200 mg, bottle, 100 count, NDC 00228-4347-11 - discontinued
- Morphine sulfate oral extended release tablet, Teva, 30 mg, bottle, 100 count, NDC 00228-4271-11 - discontinued
- Morphine sulfate oral extended release tablet, Teva, 60 mg, bottle, 100 count, NDC 00228-4311-11 - discontinued

Reason for the Shortage

- Major discontinued all morphine sulfate extended-release tablet presentations in 2025.
- Mallinckrodt refuses to provide availability information.
- Rhodes has MS Contin and morphine sulfate extended-release tablets available. Rhodes discontinued MS Contin 100 mg and 200 mg tablets.
- Sun did not provide a reason for the shortage.
- Teva discontinued morphine sulfate extended-release tablets in 2025.

Available Products

- MS Contin oral extended release tablet, Rhodes, 15 mg, bottle, 100 count, NDC 42858-0515-01
- MS Contin oral extended release tablet, Rhodes, 30 mg, bottle, 100 count, NDC 42858-0631-01
- MS Contin oral extended release tablet, Rhodes, 60 mg, bottle, 100 count, NDC 42858-0760-01
- Morphine sulfate oral extended release tablet, Rhodes, 100 mg, bottle, 100 count, NDC 42858-0804-01
- Morphine sulfate oral extended release tablet, Rhodes, 15 mg, bottle, 100 count, NDC 42858-0801-01
- Morphine sulfate oral extended release tablet, Rhodes, 200 mg, bottle, 100 count, NDC 42858-0805-01
- Morphine sulfate oral extended release tablet, Rhodes, 30 mg, bottle, 100 count, NDC 42858-0802-01
- Morphine sulfate oral extended release tablet, Rhodes, 60 mg, bottle, 100 count, NDC 42858-0803-01
- Morphine sulfate oral extended release tablet, Sun Pharma, 15 mg, bottle, 100 count, NDC 63304-0450-01
- Morphine sulfate oral extended release tablet, Sun Pharma, 200 mg, bottle, 100 count, NDC 63304-0453-01
- Morphine sulfate oral extended release tablet, Sun Pharma, 30 mg, bottle, 100 count, NDC 63304-0451-01
- Morphine sulfate oral extended release tablet, Sun Pharma, 60 mg, bottle, 100 count, NDC 63304-0758-01

Estimated Resupply Dates

- Sun has morphine sulfate 100 mg extended-release tablets on back order and the company estimates a release date in October 2025.

Updated

Updated September 19, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 12, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.